Dr. Towner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4733 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-783-4011
Summary
- Dr. William Towner is an internal medicine specialist based in Los Angeles, CA. He completed his medical education at the Keck School of Medicine of the University of Southern California in 1993, followed by internships and residencies in anesthesiology and internal medicine at UCLA and Kaiser Permanente Northern California. He has authored multiple publications on topics such as HIV, dementia, and PrEP, with several studies cited by other scholars multiple times. Dr. Towner has been involved in clinical trials focusing on HIV and hepatitis C treatment. He has received recognition for his diabetes care from the National Committee for Quality Assurance and the Health Care Incentives Improvement Institute.
Education & Training
Kaiser Permanente Northern California (San Francisco)Residency, Internal Medicine, 1995 - 1997
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Anesthesiology, 1994 - 1995- Kaiser Permanente Northern California (San Francisco)Internship, Internal Medicine, 1993 - 1994
Keck School of Medicine of the University of Southern CaliforniaClass of 1993
Certifications & Licensure
CA State Medical License 1994 - 2026- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Diabetes Recognition Program National Committee for Quality Assurance, 2009-2015
- Diabetes Care Recognition Health Care Incentives Improvement Institute
Clinical Trials
- Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects Start of enrollment: 2007 Sep 01
- Investigator-Sponsored Protocol - Continued Use of Ibalizumab Start of enrollment: 2009 Nov 01
- Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus Start of enrollment: 2011 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Safety and Immunogenicity of an mRNA-1273 Booster in Children.Vladimir Berthaud, C Buddy Creech, Christina A Rostad, Quito Carr, Liberation de Leon
Clinical Infectious Diseases. 2024-12-17 - Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.Matthew Davis, William Towner, Elliot DeHaan, Qin Jiang, Wen Li
Clinical Infectious Diseases. 2024-11-11 - Initial antiretroviral therapy regimen and risk of heart failure.Michael J Silverberg, Noel Pimentel, Wendy A Leyden, Thomas K Leong, Kristi Reynolds
AIDS. 2024-03-15
Journal Articles
- Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults with and Without HIV Infection, 2000-2016William J Towner, Michael A Horberg, JAMA Network Open
Authored Content
- Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults with and Without HIV Infection, 2000-2016June 2020
Press Mentions
C.D.C. Is Anticipated to Suggest Vaccines for Younger YoungstersJune 19th, 2022- C.D.C. Panel Meets to Vote on Covid Vaccines for Children Under 5: Live UpdatesJune 18th, 2022
- The C.D.C. Is Expected to Recommend Vaccinations of Young ChildrenJune 18th, 2022
- Join now to see all
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
